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A U T H O R

Georgianne F. Tiu

I

am a Senior working on a B.S. in Biology. I am
Executive Vice-President of the National
S o c i e t y o f C o l l e g i a t e S c h o l a rs ( 20 0 8 20 0 9 ) a n d a n A M S T E M M Re s e a rc h Fe l l ow.
Also, I have received a eUreKa! Research Grant
My future plans are to attend medical school. This
submission relates closely to my future plans because
I am highly interested in neuroscience, gerontology,
and how Alzheimer’s disease (AD) significantly affects
the character of the person who is diagnosed with
it. I am intrigued by this disease’s power to radically
change a person’s life. Not only does Alzheimer’s disease cause severe
memory loss, this disease also causes the ruthless diminishment of
cognitive thinking skills. Some people who have late-onset AD (LAD)
lose the ability to perform simple, daily tasks normal people take for
granted, such as the ability to speak or to remember one’s own name.
By working with Dr. Butterfield, I have gained much insight and
knowledge regarding AD. I was privileged to work with Dr. Butterfield’s
research group, considering that I had no prior research laboratory experience.
Dr. Butterfield mentored me through this research of AD for over a year, and
he has given me great advice on not only school-related subjects, but also on
life in general. He is someone to whom I can go for advice on applications to
graduate school, on study questions in biology, chemistry, and biochemistry,
and on what I should do to make myself a stronger student inside and outside
the classroom. I am honored that someone as prestigious as Dr. Butterfield
was able to give me a hands-on experience in science. In addition, I have
gained many friends. All of the graduate students, post-doctorates, and
research associates always offer a lending hand, and no is ever excluded.
My most important extracurricular activities are volunteering at St. Joseph
Hospital, summer clinical experiences with physicians from Harlan Appalachian
Regional Healthcare Hospital, playing the piano, exercising (which is extremely
important in the prevention of Alzheimer’s disease), cooking, and baking.
This work has been presented at the Kentucky Academy of Science, the
AMSTEMM Research Colloquium, the National Conference on Undergraduate
Research (NCUR), and the UK Showcase of Undergraduate Scholars. This
research work will be combined with the work of Dr. Sultana and plans
for submission for publication in a professional journal are underway.
As a research student on AD, I am quite optimistic that someday AD
will be a thing of the past. This success can and will be achieved as research
advances and new unknowns are solved. I believe that researchers will be
capable of solving all of the unknown facets of this disease and will be able to
synthesize a definite cure
one day. That is my hope,
and I want to be a part of
the solution. Ultimately,
I wish that everyone can
attain a full, satisfiying
life — a life filled with
memories unforgotten.
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Insights into
Alzheimer’s
Disease:
The Levels of
Signaling Proteins
in Brain of Control
Subjects Versus
Brain from Subjects
with Mild Cognitive
Impairment
eUreKa! Research and Creativity
Program Project

Faculty Mentor:
Professor D. Allan Butterfield,
Department of Chemistry
The study completed by Ms. Tiu is outstanding. It is rare
that an undergraduate is allowed to use human brain
specimens, but Ms. Tiu is so careful in her work that
an exception was made for her. Ms. Tiu found levels of
key brain proteins are altered in the brains of subjects
with mild cognitive impairment (MCI), arguably the
earliest detectable form of Alzheimer’s disease (AD).
Our laboratory’s previous research had shown that
oxidative damage to the brain in MCI is present. The
proteins whose levels are altered in MCI likely reflect
this oxidative damage, and these proteins are involved
in signaling and/or neuroinflammation. Consequently,
the significance of this research
is that the altered levels of these
proteins determined by Ms. Tiu
in the brains of subjects with
MCI strongly support the notion
that oxidative stress-induced
brain protein alterations are
important in the progression
of AD. Ms. Tiu conducted
this research and wrote the
paper by herself, with some
editing assistance from me.

Abstract
The purpose of this study was to measure the expression
levels of key signaling proteins in brain tissue from
subjects with mild cognitive impairment (MCI)
compared to control subjects. MCI is considered to be
the beginning phase of Alzheimer’s disease (AD). Tumor
necrosis factor alpha (TNF-α), nuclear factor kappa beta
(NF-κβ), phospho Bad (pBad), and ubiquitin C-terminal
hydrolase-L1 (UCH-L1) are four of the proteins that were
investigated. Trends of either decreases or increases in
protein expression levels in MCI vs. control brain were
investigated. Western blot analysis was used in order
to identify these trends. These signaling protein levels
are reportedly up-regulated or down-regulated in the AD
brain; consequently, investigating protein expression
levels in MCI brain may provide insight into how these
proteins contribute to the transition from MCI to AD.

Introduction
Alzheimer’s disease (AD) is a disheartening illness to not
only those who have developed it, but also to family and
friends of AD patients. According to current research,
it is estimated that 14-16 million Americans and more
than 22 million people around the world are expected
to develop AD in the near future, unless an intervention
can be developed (Butterfield et al., 2007). However,
that much-anticipated intervention is closer to reality
due to the efforts of Professor Butterfield and his team.
Mild Cognitive Impairment (MCI) is considered
to be the “intermediate stage between normal aging
and the AD brain” (Butterfield et al., 2007). In the
early stages of MCI, many people go on living their
daily lives quite normally. However, in amnestic MCI
there is a noticeable decline of memory compared to
prior years, but there are no signs of dementia in the
early stages. Still, some researchers consider MCI to
be the earliest stage of AD. Using redox proteomics to
investigate molecular aspects of AD and MCI, Professor
Butterfield’s team has tracked and recorded the degrading
effects of oxidative stress (Butterfield et al., 2007).
Earlier studies have illustrated the importance of
oxidative stress in the pathogenesis of AD. Oxidative
stress is caused by an imbalance between the production
of toxic reactive oxygen species (ROS) and the
body’s antioxidant systems. Protein oxidation can
lead to extracellular amyloid plaques, intracellular
neurofibrillary tangles, oligomers of amyloid β-peptide
(Aβ), and synapse loss (Butterfield et al., 2007).
The Aβ (1-42) peptide is the peptide of interest in
the study of AD pathology. Aβ (1-42) is a peptide
that is derived from the proteolytic cleavage of a
Type I integral membrane protein known as amyloid
precursor protein (APP) and is thought to underlie

the pathogenesis of AD (Butterfield et al., 2007).
Protein oxidation causes notable adverse effects.
Oxidation of proteins can cause protein dimerization,
in which two molecules of the same chemical
composition can form a condensation product. In
addition, protein oxidation can lead to denaturation
of proteins, a process in which a protein unfolds from
its usual structure, and its normal conformation is
lost. This process is detrimental because the unfolding
allows the hydrophobic (“water-fearing”) amino acid
residues to be exposed to the aqueous environment.
This exposure can lead to a loss of structural or
functional activity and cause protein aggregation, such
as tau aggregation that is evident in the AD brain.
Tau aggregation is responsible for forming the
neurofibrillary tangles, while senile plaques are
composed of extracellular, fibrillar Aβ (1-42) that
histopathologically characterize the AD brain. The senile
plaques are associated with activated astrocytes and
copious amounts of microglia at the site of deposition
of Aβ (1-42) in AD (Bernhardi and Eugenin, 2004).
Furthermore, the activation of the inflammatory
response is thought to be crucial in quantifying the
rate of the neurodegenerative process (McGeer and
McGeer, 1998). β-Amyloid activates glia to synthesize
an assortment of inflammatory factors such as
tumor necrosis factor-alpha (TNF-α), reactive oxygen
species (ROS), nitric oxide (NO) and inducible nitric
oxide synthase (iNOS), which may increase the
rate of the development of AD (Jiang et al., 2007).

Materials
All chemicals used were purchased from Sigma-Aldrich
(St. Louis, MO) with the exception of nitrocellulose
membranes (Bio-Rad, Hercules, CA), electrophoretic
transfer system (Trans-blot Semi-dry Transfer Cell; BioRad), and Western blotting (Calbiochem, LA Jolla, CA).

Subjects
The University of Kentucky Rapid Autopsy Program
of the Alzheimer’s Disease Clinical Center (UK ADC)
provided frozen hippocampus samples from MCI
subjects and age-matched controls. The patients were
diagnosed with probable MCI according to criteria
produced by the National Institute of Neurological and
Communicative Disorders and Stroke (NINCDS) and the
Alzheimer’s Disease and Related Disorders Association.
The control subjects did not have any neurological
disorders nor did they have a history of dementia.
They had undergone annual mental status testing and
semiannual physical and neurological examinations as
part of the UK ADC normal volunteer longitudinal aging
study. Table 1 describes the background of the patients.
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Table 1. Characteristics of control and MCI patients (mean ± SD).
Demographic variables

Control Subjects

MCI Subjects1

Number of subjects
Gender (male/female)
Postmortem Interval (hours)
Brain weight (grams)
Braak2 stage		

7			
3/4		
2.87±1.14
1260±120
I-II		

7
3/4
3.125±1.033
1120±61
III-V

1.
2.

MCI: mild cognitive impairment
The standard, six-stage description of
a patient’s level of AD, from extremely
mild to full-blown dementia, named for
the German researcher who developed
the scale.

Sample preparation
The brain tissues (hippocampus) from controls and
MCI subjects were homogenized in ice-cold isolation
buffer containing 10mM Hepes buffer, 137mMNaCl,
4.6 mM KCl, 1.1 mM KH2PO4, and 0.6 mM MgSO4,
as well as proteinase inhibitors leupeptin (0.5 mg/
ml) and pepstatin (0.7 mg/ml). Homogenates were
centrifuged at 14,000 g for 10 min to remove debris.
The supernatant was extracted to determine the
total protein concentration by the BCA method.
Twenty µl of either 150 µg or 100 µg of control
and MCI samples from the hippocampus (one of the
first regions of the brain to suffer damage from AD)
were used in the 1D Western blots. 1D Western Blots
were used to determine the protein expression levels
in control and MCI brain tissues. Gel electrophoresis
was utilized to separate the denatured control and MCI
brain proteins, and the proteins were then transferred
to a nitrocellulose membrane. Primary and secondary
antibodies detected the proteins that were on the blot.
The science underlying tagging antibodies is actually
quite simple. First, an animal such as a rabbit is injected
with a protein, such as TNF-α. The rabbit’s immune system
then produces antibodies against the foreign protein,
TNF-α. The antibodies are then collected and are called
primary antibodies. A second animal, such as a goat,
is injected with the primary antibodies that the rabbit’s
immune system created. The goat’s immune system then
creates antibodies against the newly injected primary
antibodies and the secondary antibodies are thus created.

Western blotting analysis
In the process of Western blotting, a primary antibody
is added to the nitrocellulose membrane in order to tag
the protein of interest, such as TNF-α. The secondary
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antibody then tags and recognizes the primary
antibodies. Specific substrates, 5-bromo-4-chloro-3indolyl-phosphate and nitroblue tetrazolium (BCIP
and NBT), are then used to catalyze the reaction
and develop the blot so that the proteins can be
seen. A purple color is the result of the reaction. A
distinctive band of the specific protein is expected to
show up first, especially with monoclonal antibodies.
There are two different kinds of antibodies used in
this project — monoclonal and polyclonal antibodies.
Monoclonal antibodies are specific for certain amino
acid sequences and their motifs. A blot that uses
monoclonal antibodies usually shows fewer bands
than polyclonal because monoclonal antibodies are
more specific to the particular protein’s amino acid
sequence. With the case of polyclonal antibodies, more
bands show up because repeating amino acid motifs
in proteins other than the particular protein of interest
(TNF-α for example) are tagged as well. However,
because each protein has its own molecular weight,
determining which band belongs to the protein of
interest is not difficult. The blots are then scanned with
Adobe Photoshop and quantified with Scion Image (PC
version of Macintosh-compatible NIH Image) software.

Tumor Necrosis Factor-Alpha, TNF-α
Tumor necrosis factor-alpha (TNF-α) is a member
of a cytokine family that can cause cell apoptosis
(programmed cell death) and cellular proliferation
and differentiation. Cellular differentiation can be
observed in macrophages, inflammatory cells that
originate from white blood cells. TNF-α is produced
by specific cells of the immune system in response
to adverse conditions, such as exposure to ionizing
radiation, elevated temperature, viral infection, or
toxic chemical agents such as those used in cancer
chemotherapy (Karp, G., 2005; Tangpong et al.,
2006). TNF-α is a pro-inflammatory cytokine that
participates in inflammation, cell survival, and cell
death processes (Gomez-Chiarri et al., 1994) and can
trigger cell death through cell apoptosis and necrosis.
This particular cytokine is a signaling protein that
is secreted from immune system cells that ultimately
changes the action of other immune cells. TNF-α
regulates immune cells and causes inflammatory responses. These inflammatory responses are necessary
in order to defend the body against pathogens. However, increased levels of inflammation are evident in
neurodegenerative disorders and are implicated in the
etiology of Alzheimer’s disease, Parkinson’s disease, and
ischemia (Lovell et al., 1998; Liao et al., 2001; Gao et
al., 2002). In mice treated with pro-oxidant adriamycin
or in AD brain, neuroinflammation arbitrated from glia
overproduction or dysfunctional regulation of TNF-α
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is observed (Jiang et al., 2007; Tangpong et al., 2008).

Mechanism
In its normal mechanism of signaling cell apoptosis,
TNF-α first binds to its receptor, either TNFR1 or
TNFR2. TNFR1 is the receptor that is constitutively
expressed in most tissues. The activated receptor then
binds TRADD and FADD, two cytoplasmic adaptor
proteins, and procaspase-8 to create a complex that is
located on the inner surface of the plasma membrane.
FADD and TRADD interact with each other in regions
known as death domains, and procaspase-8 and
FADD interact with each other in what are known as
death effector domains. Once assembled together,
the procaspase molecules cleave each other to create
Caspase-8, an initiator complex that directs the cell to
its final destination of cell apoptosis. It is important
to note, however, that after TRADD binding, two other
pathways can be initiated. They will be discussed later.

Hypothesis and Data

Figure 1. TNF-α Protein Levels in Control and MCI Hippocampus
(A) Western blot with ten lanes. Lanes 1-5 are control samples. Lanes
6-10 are MCI samples. (20 µl of 100 µg samples were added to each well.)
Lanes 6 and 8 display the significant increase in TNF-α protein levels. (B)
Graphical analysis of control and MCI band intensities, respectively. The
graph illustrates the significant increase in TNF-α from control and MCI
comparison. (p < 0.01). C-HP, control hippocampus; MCI-HP, MCI hippocampus.

Because neuroinflammation is elevated in the AD
brain, I hypothesized that neuroinflammation can be
observed in the MCI brain. Therefore, TNF-α levels
are hypothesized to be increased in the MCI brain
samples. The results thus far confirm my hypothesis.
Brain tissue was obtained from five different subjects
(n = 5) for both control and MCI. There is a clearly
significant increase in TNF-α protein levels in MCI.
(p < 0.01). There is variation due to the biological
nature of the samples from human individuals.

Nuclear Factor-Kappa Beta, NF-κβ
As explained above, after TRADD binding, two other
pathways other than cell apoptosis can be initiated. One
pathway is the activation of NF-κβ . The other pathway
is the activation of the MAPK pathways. The protein
in this particular study was the p65 subunit of NF-κβ .

Mechanism
In its normal function, after TRADD binds to the death
domain, TRADD assembles TRAF2 and RIP, a serinethreonine containing kinase. TRAF2 then recruits
protein kinase, IKK, a multi-component protein. This
recruitment permits RIP to activate IKK. An inhibitory
protein that is bound to NF-κβ, known as I, inhibits
NF-κβ from translocation. I is then phosphorylated
by IKK and is degraded. This process releases NFκβ so that it can translocate to the nucleus. NF-κβ is
a transcription factor that initiates the synthesis of
proteins that are involved in anti-apoptotic factors,

Figure 2. NF- κβ Protein Levels in Control and MCI Hippocampus
(A) Western blot with eight lanes. Lanes 1-4 are control samples. Lanes 5-8 are MCI
samples. (20 µl of 100 µg samples were added to each well.) Lane 6 of MCI clearly
displays a higher intensity of protein concentration than the control samples and
illustrates an increase in NF-κβ protein levels in MCI. Lane 7’s value was thrown
out after a Q-test was performed (B) Lane 1 and 2 are control. Lanes 3-5 are MCI
samples. (C) Graphical analysis of control and MCI band intensities, respectively.
The graph illustrates an increase in NF-κβ from control and MCI comparison. C-HP,
control hippocampus; MCI-HP, MCI hippocampus. (p=0.06; it is near significant)

T H E U N I V E R S I T Y O F K E N T U C K Y J O U R N A L O F U N D E R G R A D U AT E S C H O L A R S H I P

65

the hypothesis of a trend toward an increase in NF-κβ
levels in MCI brain, and the results also illustrate near
significance as assessed by the Wilcox p-value of 0.06.

Phospho Bad (Serine 112) (Phosphorylated Bcl-2 associated death
promoter)

Figure 3. Phospho Bad Protein Levels in Control and MCI Hippocampus
(A) Western blot with eight lanes. Lanes 1-4 are control samples. Lanes 5-8 are MCI
samples. (20 µl of 100 µg samples were added to each well.) (B) Graphical analysis
of control and MCI band intensities, respectively. The graph illustrates no change from
control and MCI comparison. C-HP, control hippocampus; MCI-HP, MCI hippocampus.

inflammation, and cell survival and proliferation.

Hypothesis and Data
Because p65 of NF-κβ is a transcription factor that
mediates the transcription for cell survival and antiapoptotic factors, I hypothesized that there will be an
increase in p65 of NF-κβ in the MCI brain, because
neuroinflammation and pro-apoptotic factors are expected
to be increased in the AD brain. NF-κβ can provide the
brain with neuroprotection, and if NF-κβ is not released
into the nucleus, the result will be a lack of important,
protective proteins. According to prior research, p50/p65
of NF-κβ, has been reported to be activated in AD brain
(Kaltschmidt et al., 1997; Yan et al., 1995; Yoshiyama et
al., 2001). According to that research, p65 is expected
to be increased in AD brain. However, is there an
increase of p65 in MCI brain? There have been several
studies that demonstrate that, if NF-κβ is introduced to
an inhibitor, or even its inhibitory protein, I , is blocked
with a repressor, the protective effects are nullified.
Nakao et al. (2008) demonstrated that galantamine
(a drug that is currently being used to treat mild to
moderate AD) and its protective effects are nullified with
the inhibition of NF-κβ or the repression of its bound
protein, I. This finding suggests that NF-κβ is crucial in
the reduction of inflammation and the mechanism of
defense. Therefore, it is hypothesized that there will be
an increase in NF-κβ levels in MCI. My results support
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Bad is a member of the B cell leukemia-2 (Bcl-2)
gene family. When Bad is phosphorylated, it is
called phospho Bad (p-Bad). Serine 112 phospho Bad
was used in this study. Alterations in phospho Bad
antagonize apoptosis function in Bad (Jeong et al.,
2007). Oxidative stress can cause alterations in protein
expression and perhaps efficiency. Bad’s main role is
to signal cell apoptosis to cells that may be damaged,
from oxidative stress for example. Phosphorylation
initiates Bad to signal pro-apoptotic pathways in order
to rid the brain of damaged components of a cell.

Mechanism
Oxidative stress is one factor that causes cellular stress
that ultimately leads to cell apoptosis. Cellular stress
causes a pro-apoptotic factor such as Bad to insert itself
into the outer mitochondrial membrane. The insertion of
the protein, Bad, then signals the release of cytochrome
c molecules from the intermembrane space of the
mitochondria. When the cytochrome c molecules are
translocated to the cytosol, they form a multi-subunit
complex with caspases that then, in turn, activate the
downstream executioner caspases that cause apoptosis.

Hypothesis and Data
Because phospho Bad’s function is to cause cell
apoptosis, it is hypothesized that there will be a decrease
in phospho Bad protein levels in MCI brains in order
to provide neuroprotection from oxidative stress. The
reason for this decrease is that when an environmental
factor, such as oxidative stress, affects the brain cells,
phospho Bad is signaled to cause pro-apoptotic caspases
to rid the brain of damaged ells and to regulate the cell
death processes. In the normal brain, I hypothesized that
a decrease in phospho Bad activity or a loss of function
could result in the aggregation of unwanted proteins.
The data below illustrate no change in phospho
Bad protein levels in MCI brain, suggesting that these
unchanging levels contribute to unwanted protein
accumulation and neuronal toxicity in AD brain. Yoon et
al. (2006), support these data, stating that the “cultured
neurons have shown that okadaic acid (OA) evokes tau
phosphorylation to initiate a neurodegeneration that
resembles the pathogenesis of AD. Western blotting
revealed that … expression of Bad was decreased
as early as 4 hours after OA treatment, although the
level of phospho Bad was relatively constant.” These
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levels were observed in cultured cortical neurons.

Ubiquitin Carboxyl Terminal Hydrolase L1 (UCH-L1)
Ubiquitin C-terminal hydrolase L1 (UCH-L1) is an enzyme
that is a main component of the ubiquitin proteasome
system and has catalytic hydrolase properties that can
hydrolyze peptide-ubiquitin bonds and recycle ubiquitin
monomers to be used again in the same process (Healy et
al., 2004). UCH-L1 is a member of the deubiquitylating
enzymes and is one of the most abundant proteins
in the brain. Whereas other UCH members are
ubiquitously expressed, UCH-L1 is selectively expressed
in neurons (Sakurai et al., 2006; Wilkinson et al., 1989).
Moreover, it is an enzyme involved in the process
of proteolytic degradation of misfolded or damaged
proteins by the proteasome (Castegna et al., 2002).
Analysis of proteasome function in post-mortem
human AD brains has shown a strong inhibition of activity
in the proteasome and lower protein levels for UCH-L1,
suggesting that the neuronal ubiquitin-proteasomal
system is linked to the pathogenesis of AD (Gong et al.,
2006). Research from our lab also confirmed a decrease
of UCH-L1 activity in AD brain. According to Sultana
et al. (2006), the measurement of enzymatic activity
of CA II, UCHL-1, and enolase from AD hippocampus
revealed decreased activity compared to control.
UCH-L1 is important for proteasomal-mediated
clearance from the brain of aggregated or misfolded
proteins. Protein aggregation, such as tau aggregation,
is seen in the AD brain. The decline of UCH-L1
proteasomal activity likely contributes to protein
aggregation and thus neuronal toxicity. Less UCH-L1
in MCI brain is predicted to result in more ubiquinated
proteins, decreased activity of the 26S proteasome,
and consequently, an accumulation of aggregated and
damaged proteins. All were observed in MCI brain.
Because there is evidence of a decline in UCH-L1
activity in AD brain (Sultana et al., 2006), I hypothesized
that there will be a decline of UCH-L1 protein levels in the
MCI brain as well. The results below support my hypothesis.

Statistics
For all trials, a Student’s t-Test was performed in order
to determine significance. Q-test analysis was also
performed to determine the outliers for statistical analysis.
The results are presented as the mean plus or minus the
standard deviation. Because biological samples were
used in this project, variation was expected to occur.

Discussion
Because NF-κβ is downstream from TNF-α, it is
hypothesized that there will be a proportional relationship
between the two proteins. If TNF-α increases in the

Figure 4. UCH-L1 Protein Levels in Control and MCI Hippocampus
(A) Western blot with eight lanes. Lanes 1-4 are control samples. Lanes 5-8 are MCI
samples. (20 µl of 100 µg samples were added to each well.) Lanes 1 and 2 (control)
clearly display higher intensities than the MCI samples and illustrate the significant
decrease in UCH- L1 protein levels in MCI. (B) Lanes 1 and 2 are control samples.
Lanes 3-5 are MCI samples. (C) Graphical analysis of control and MCI band intensities,
respectively. The graph illustrates the significant decrease in UCH- L1 from control and
MCI comparison. (p < 0.05). C-HP, control hippocampus; MCI-HP, MCI hippocampus.

brain, then NF-κβ is expected to increase as well. The
increase in oxidative stress creates a signal that antiapoptotic factors from NF-κβ need to be synthesized.
Phospho Bad is pro-apototic, which means
that it causes cell death. When TNF-α is activated,
because of oxidative stress for example, NF-κβis
activated in order to create proteins that can
counteract the oxidative stress. Phospho Bad activates
downstream caspases that ultimately lead to cell
apoptosis. The unchanging levels of phospho Bad
offer an explanation if there is an accumulation of
unwanted proteins and neuronal toxicity in MCI.
The unchanging levels of phospho Bad in AD brain
can be tied to the decrease in UCH-L1 activity. UCH-L1
is known to be decreased in AD brain (Castegna et
al., 2002; Sultana et al., 2006). This finding means
that its normal functional levels are decreased and
therefore lead to histopathological characteristics that
are evident in the AD brain. For example, less UCH-L1
in MCI brain is predicted to result in more ubiquinated
proteins, decreased activity of the 26S proteasome,
and, consequently, an accumulation of aggregated
and damaged proteins. All are observed in MCI brain.
UCH-L1 is a member of the deubiquitylating
family. It is part of the proteasome pathway that
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rids the brain of protein aggregations and misfolded
proteins. UCH-L1’s down-regulated levels that are
evident in AD brains contribute to neuronal toxicity,
because unwanted proteins accumulate in the brain.
Because oxidative stress signals TNF-α production and,
therefore, NF-κβ is signaled to produce proteins that help
to counteract oxidative stress, phospho Bad is signaled
to induce apoptosis to dispose the damaged proteins.
UCH-L1 is affected by oxidative stress as well.
Because UCH-L1’s proteasomal and degradative
properties are decreased in both MCI and AD brain,
this means that UCH-L1 cannot rid the brain of
damaged, unwanted proteins. This failure will
result in protein aggregation and neuronal toxicity.

Conclusion
Through this research, new insights into the
histopathology and biochemical alterations observed
in MCI brain have been found. Data presented in this
paper illustrated that there is an increased level of
oxidative stress in MCI supported by increased levels
of TNF-α, NF-κβ, and decreased levels of UCH-L1.
Phospho Bad’s unchanging protein expression levels
could mean that there is no activation of pro-apoptic
pathways stimulated by this pathway, and that could lead
to an accumulation of damaged components in brain.
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